Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis

[1] Whelan TJ(2011)Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials Lancet 378 1707-1716

[2] Pignol J-P(2014)Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials Lancet 383 2127-2135

[3] Levine MN(2010)Long-term results of hypofractionated radiation therapy for breast cancer N Engl J Med 362 513-520

[4] Julian JA(2008)The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet Oncol 9 331-341

[5] MacKenzie R(2008)The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet 371 1098-1107

[6] Parpia S(2019)Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial Lancet Oncol 20 352-360

[7] Wang S-L(2013)The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials Lancet Oncol 14 1086-1094

[8] Fang H(2011)Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline Int J Radiat Oncol 81 59-68

[9] Song Y-W(2018)Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline Pract Radiat Oncol 8 145-152

[10] Wang W-H(2016)Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey BMJ 352 i493-13

[1] Whelan TJ(2011)Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials Lancet 378 1707-1716

[2] Pignol J-P(2014)Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials Lancet 383 2127-2135

[3] Levine MN(2010)Long-term results of hypofractionated radiation therapy for breast cancer N Engl J Med 362 513-520

[4] Julian JA(2008)The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet Oncol 9 331-341

[5] MacKenzie R(2008)The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet 371 1098-1107

[6] Parpia S(2019)Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial Lancet Oncol 20 352-360

[7] Wang S-L(2013)The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials Lancet Oncol 14 1086-1094

[8] Fang H(2011)Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline Int J Radiat Oncol 81 59-68

[9] Song Y-W(2018)Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline Pract Radiat Oncol 8 145-152

[10] Wang W-H(2016)Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey BMJ 352 i493-13